FDA to import more Chinese cancer drugs amid shortage

0

The Food and Drug Administration (FDA) is opening the way for more cancer drugs from China as the U.S. continues to deal with an ongoing shortage in key chemotherapy treatments.

A spokesperson for the FDA confirmed on Monday that the agency is permitting 10 additional lots of the common cancer drug cisplatin to be distributed by the Chinese company Qilu Pharmaceutical.

Cisplatin is currently under shortage along with another common cancer drug carboplatin. These two drugs, oftentimes prescribed together, are used to treat a wide variety of cancers such as those of the breast, lung and prostate.

The latest move was first reported by Bloomberg.

The FDA last month issued a letter allowing the “Temporary Importation of CISplatin Injection with non-U.S. Labeling” in order to address the shortage of chemotherapy medications. At the time, four lots were allowed to be distributed.

While cisplatin is a commonly used drug in the U.S., the cisplatin product being imported by Qilu — manufactured and marketed in China — is not FDA-approved.

Much of the current shortage is tied to the temporary closure of a manufacturing facility in India owned by Intas Pharmaceuticals. The closure occurred after the FDA discovered “failures” in the plant’s quality control. The company is working with the FDA to restart production.

Last month, the agency issued an import alert on the facility in India which would deny entry for all products made at that location except 24 drugs that are in short supply, including cisplatin.

The current shortage has brought heightened attention on the tenuous nature of drug supply lines for medicines in the U.S.

The shortage is also partly due to drug manufacturers lacking an incentive to invest in generic drugs, which have smaller profit margins. This has lead to a limited number of generic facilities operating at near-capacity.

Copyright 2023 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Health & Fitness News Click Here 

Read original article here

Denial of responsibility! Rapidtelecast.com is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
Leave a comment